AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6810015 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin preparation given once daily at variable doses
Number of subjects: 26
Study 6810015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31496287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 3 months
Number of subjects: 60
Study 31496287 — intervention group
Group type: COMPARATOR
Intervention: Standard diet for 3 months
Number of subjects: 60
Study 31097413 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity counseling (TC)
Number of subjects: 64
Study 31097413 — intervention group
Group type: COMPARATOR
Intervention: Education (EC)
Number of subjects: 64
Study 27997274 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative programme (8 sessions, 2 hours each) with 2-year outpatient follow-up
Number of subjects: 80
Study 27997274 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-year outpatient follow-up only)
Number of subjects: 80
Study 25913664 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-582949 (100 mg once daily)
Number of subjects: 72
Study 25913664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 72
Study 25913664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25004983 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid plus patient navigation
Number of subjects: 300
Study 25004983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 300
Study 21295198 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin management communication protocol using SBAR approach
Number of subjects: 435
Study 21295198 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard communication)
Number of subjects: 435
Study 19390548 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of etoposide to cyclophosphamide and ifosfamide in patients with large, localized tumors
Number of subjects: 0
Study 19390548 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and ifosfamide
Number of subjects: 0
Study 17342644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted guideline-implementation strategy tailored to baseline performance
Number of subjects: 1906
Study 17342644 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1906
Study 15261316 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (50 mg kg(‐1) in 100 mL saline, followed by 50 mL hr(‐1) infusion of MgSO4 (15 mg kg(‐1) hr(‐1))
Number of subjects: 50
Study 15261316 — intervention group
Group type: COMPARATOR
Intervention: Saline (equal volume to MgSO4)
Number of subjects: 50
Study 11389256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide treatment for PPHN
Number of subjects: 83
Study 11389256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitric oxide treatment)
Number of subjects: 83
Study 9244079 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture (3/0 prolene)
Number of subjects: 80
Study 9244079 — intervention group
Group type: COMPARATOR
Intervention: Metal clips (Michel clips)
Number of subjects: 80
Study 8302758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound massage (3.0 MHz, 1.0 W/cm2 continuous output) for 5 min
Number of subjects: 10
Study 8302758 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage (0 MHz) for 5 min
Number of subjects: 10
Study 3103731 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic sphincterotomy and stone clearance (group 1)
Number of subjects: 120
Study 3103731 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (group 2)
Number of subjects: 120
Study 29297698 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin combined with paclitaxel
Number of subjects: 0
Study 29297698 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with paclitaxel
Number of subjects: 0
Study 26376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.5, 3, 10, or 15 mg twice daily)
Number of subjects: 194
Study 26376350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 26376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 194
Study 24091694 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1521 vaccine
Number of subjects: 60
Study 24091694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22842667 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1‐34) 20 μg
Number of subjects: 30
Study 22842667 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1‐84) 100 μg
Number of subjects: 30
Study 22842667 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated osteoporotic women)
Number of subjects: 30
Study 20226809 — intervention group
Group type: COMPARATOR
Intervention: Written materials
Number of subjects: 96
Study 20226809 — intervention group
Group type: COMPARATOR
Intervention: Written materials plus a one-page form for dietary planning
Number of subjects: 96
Study 20226809 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials, one-page form, and telephone counseling from a dietitian
Number of subjects: 96
Study 18937830 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 12 weeks
Number of subjects: 24
Study 18937830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15986951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleached groups treated with peroxide bleaching regimens
Number of subjects: 70
Study 15986951 — intervention group
Group type: COMPARATOR
Intervention: Unbleached control group
Number of subjects: 70
Study 11986563 — intervention group
Group type: EXPERIMENTAL
Intervention: static with motion correction (MC) only
Number of subjects: 66
Study 11986563 — intervention group
Group type: EXPERIMENTAL
Intervention: gated with MC only
Number of subjects: 66
Study 11986563 — intervention group
Group type: EXPERIMENTAL
Intervention: static with MC plus blur correction plus AC (combined corrections [CC])
Number of subjects: 66
Study 11986563 — intervention group
Group type: EXPERIMENTAL
Intervention: gated with CC
Number of subjects: 66
Study 12873166 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV triage testing
Number of subjects: 5050
Study 12873166 — intervention group
Group type: COMPARATOR
Intervention: Immediate colposcopy
Number of subjects: 5050
Study 12873166 — intervention group
Group type: COMPARATOR
Intervention: Cytologic follow-up
Number of subjects: 5050
Study 12873166 — intervention group
Group type: COMPARATOR
Intervention: HPV DNA testing by Hybrid Capture 2
Number of subjects: 5050
Study 9653864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose danazol (600 mg daily)
Number of subjects: 120
Study 9653864 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose danazol (200 mg daily) plus placebo tablets
Number of subjects: 120
Study 9653864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7664720 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically fermented milk product (200 ml/day)
Number of subjects: 58
Study 7664720 — intervention group
Group type: COMPARATOR
Intervention: Placebo product (200 ml/day)
Number of subjects: 58
Study 2474017 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L5HTP; 100 mg qid) with carbidopa (C; 50 mg qid)
Number of subjects: 8
Study 2474017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 965302 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 100% O2
Number of subjects: 5
Study 965302 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 21% O2
Number of subjects: 5
Study 965302 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 12% O2
Number of subjects: 5
Study 31014382 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 71
Study 31014382 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 71
Study 29107949 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brush (ECB)
Number of subjects: 200
Study 29107949 — intervention group
Group type: COMPARATOR
Intervention: Endocervical curette (ECC)
Number of subjects: 200
Study 26580831 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycerol trinitrate (2g once a day for 3 days before laser sessions)
Number of subjects: 83
Study 26580831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 23229188 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg/week)
Number of subjects: 40
Study 23229188 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (2.5 mg/kg/day)
Number of subjects: 40
Study 21818510 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 81
Study 21818510 — intervention group
Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 81
Study 19451425 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/LV5FU2
Number of subjects: 2094
Study 19451425 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 2094
Study 16461867 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care, office‐based, computer‐assisted diet and PA assessment and stage‐based goal setting followed by brief health care provider counseling and 12 months of monthly mail and telephone counseling
Number of subjects: 878
Study 16461867 — intervention group
Group type: COMPARATOR
Intervention: Sun protection condition
Number of subjects: 878
Study 15056197 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of numerical estimation on 0‐to‐100 number lines
Number of subjects: 3
Study 15056197 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to relevant experience
Number of subjects: 3
Study 15056197 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences in number‐line estimation
Number of subjects: 3
Study 11787317 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 29
Study 11787317 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 29
Study 9287262 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mmol/day potassium supplement for four weeks
Number of subjects: 8
Study 9287262 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mmol/day potassium supplement for four months
Number of subjects: 8
Study 9287262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8346578 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) therapy - intravenous methylprednisolone 2 mg/kg bodyweight daily for ten days
Number of subjects: 59
Study 8346578 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (standard treatment)
Number of subjects: 59
Study 3555175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg three times a day for two weeks
Number of subjects: 20
Study 3555175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30679318 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 724
Study 30679318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 724
Study 27646064 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ Care System
Number of subjects: 38
Study 27646064 — intervention group
Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 38
Study 26383218 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Assertiveness Training
Number of subjects: 57
Study 26383218 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 57
Study 22927230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 ng/mL (group SL)
Number of subjects: 42
Study 22927230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 ng/mL (group SH)
Number of subjects: 42
Study 21353695 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneous every 4 weeks)
Number of subjects: 1904
Study 21353695 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (4 mg intravenous every 4 weeks)
Number of subjects: 1904
Study 21353695 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1904
Study 21353695 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1904
Study 19608171 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiologic (0.2 mg/d transdermal E(2) and vaginal micronized E(2))
Number of subjects: 18
Study 19608171 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic (0.2 mg/d transdermal E(2))
Number of subjects: 18
Study 19608171 — intervention group
Group type: COMPARATOR
Intervention: Subphysiologic (no exogenous E(2) treatment)
Number of subjects: 18
Study 19608171 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 18
Study 17051443 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Communication Assessment for Toddlers with Autism (SCATA)
Number of subjects: 0
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (high dose) 480/240 mg/d
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (low dose) 320/160 mg/d
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/d
Number of subjects: 1033
Study 15321697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (high dose)
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (low dose)
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (Quinidine + Verapamil high dose, low dose, Sotalol)
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil and Sotalol
Number of subjects: 1033
Study 15321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil
Number of subjects: 1033
Study 11446451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in glaucoma participants
Number of subjects: 3271
Study 11446451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in non-glaucoma participants
Number of subjects: 3271
Study 11446451 — intervention group
Group type: COMPARATOR
Intervention: Non-operated eyes in glaucoma participants
Number of subjects: 3271
Study 11446451 — intervention group
Group type: COMPARATOR
Intervention: Non-operated eyes in non-glaucoma participants
Number of subjects: 3271
Study 9671326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg three times weekly
Number of subjects: 0
Study 9671326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 7803947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline, dothiepin, mianserin, trazodone
Number of subjects: 0
Study 7803947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline, maprotiline, amitriptyline
Number of subjects: 0
Study 7803947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 7803947 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study 7803947 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors
Number of subjects: 0
Study 3288951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg at suppertime for 28 days
Number of subjects: 30
Study 3288951 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 30
Study 30035576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (12-24 hr abstinence)
Number of subjects: 137
Study 30035576 — intervention group
Group type: COMPARATOR
Intervention: Continued ad lib smoking
Number of subjects: 137
Study 30035576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (12-24 hr abstinence) among smokers who reported no pain at baseline
Number of subjects: 137
Study 28821940 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible endoscopic evaluation of swallowing with endoscope insertion
Number of subjects: 37
Study 28821940 — intervention group
Group type: COMPARATOR
Intervention: Videofluoroscopy without endoscope insertion
Number of subjects: 37
Study 26322666 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-1000
Number of subjects: 267
Study 26322666 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-30,000
Number of subjects: 267
Study 26322666 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-1000
Number of subjects: 267
Study 26322666 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-30,000
Number of subjects: 267
Study 26322666 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir + lamivudine
Number of subjects: 267
Study 24082090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic mental simulations
Number of subjects: 0
Study 20411996 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 10 mg/day
Number of subjects: 33
Study 20411996 — intervention group
Group type: COMPARATOR
Intervention: CEE 0.6 mg/day
Number of subjects: 33
Study 18182939 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan and estradiol
Number of subjects: 51
Study 18182939 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan alone
Number of subjects: 51
Study 18182939 — intervention group
Group type: COMPARATOR
Intervention: Estradiol and placebo
Number of subjects: 51
Study 18182939 — intervention group
Group type: COMPARATOR
Intervention: Placebo/placebo
Number of subjects: 51
Study 16582549 — intervention group
Group type: EXPERIMENTAL
Intervention: QUANTEC treatment for 3 months
Number of subjects: 34
Study 16582549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment during first phase)
Number of subjects: 34
Study 15806847 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% protein)
Number of subjects: 11
Study 15806847 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (55% carbohydrate)
Number of subjects: 11
Study 11061470 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg aqueous nasal spray
Number of subjects: 25
Study 11061470 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 256 microg aqueous nasal spray
Number of subjects: 25
Study 8655889 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 30
Study 8655889 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 200 micrograms twice daily
Number of subjects: 30
Study 1417196 — intervention group
Group type: EXPERIMENTAL
Intervention: New polyvalent melanoma cell vaccine (MCV)
Number of subjects: 136
Study 1417196 — intervention group
Group type: COMPARATOR
Intervention: Historical database of previous immunotherapy and other treatments
Number of subjects: 136
Study 2864709 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam per day
Number of subjects: 45
Study 2864709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg fluspirilene per week
Number of subjects: 45
Study 31012968 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intervention group (Garmin Vivofit 2 + behavioral feedback + goal-setting + 5 health coaching sessions)
Number of subjects: 80
Study 31012968 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (Garmin Vivofit 2 only)
Number of subjects: 80
Study 30266894 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐flu/val (10 mg/20 mg)
Number of subjects: 36
Study 30266894 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 27514243 — intervention group
Group type: EXPERIMENTAL
Intervention: Five year screening and lifestyle counselling programme (n=11,629)
Number of subjects: 59616
Study 27514243 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=47,987)
Number of subjects: 59616
Study 25236838 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (AA)
Number of subjects: 119
Study 25236838 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 119
Study 22381137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition on the Go intervention (decreased energy content of school breakfasts, increased fruits and vegetables, increased physical activity, and water consumption)
Number of subjects: 1020
Study 22381137 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard school breakfast without intervention)
Number of subjects: 1020
Study 22381137 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between intervention and stage
Number of subjects: 1020
Study 22381137 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls in the intervention group
Number of subjects: 1020
Study 20855047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 112
Study 20855047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 112
Study 20855047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Sertraline and CBT (COMB)
Number of subjects: 112
Study 20855047 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 112
Study 20855047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) without family history of OCD
Number of subjects: 112
Study 17939880 — intervention group
Group type: EXPERIMENTAL
Intervention: From Home To Operation (FHTO)
Number of subjects: 47
Study 17939880 — intervention group
Group type: COMPARATOR
Intervention: Conventional ward procedures
Number of subjects: 47
Study 14752209 — intervention group
Group type: COMPARATOR
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 112
Study 14752209 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine
Number of subjects: 112
Study 14752209 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH insufficiency management
Number of subjects: 112
Study 14752209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 112